Checkpoint Therapeutics, Inc. Stock News

UNLOXCYT™  (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Checkpoint Therapeutics, Inc. (NasdaqCM: CKPT) to Sun Pharmaceutical Industries Limited. Under the terms of the proposed transaction, shareholders of Checkpoint will receive $4.10 per share and a c...

UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Checkpoint Therapeutics, Inc. (NasdaqCM: CKPT) to Sun Pharmaceutical Industries Limited. Under the terms of the proposed transaction, shareholders of Checkpoint will receive $4.10 per share and a contin...

PHILADELPHIA, March 13, 2025 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating the fairness of the recently announced buyout of Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT) shareholders.

NEW YORK , March 10, 2025 /PRNewswire/ -- Shareholder law firm Julie & Holleman LLP is investigating the proposed $4.10 per share sale of Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) to Sun Pharmaceutical Industries, Inc. The firm is concerned about conflicts relating to Checkpoint's controlling shareholder, Fortress Biotech, Inc. (Nasdaq: FBIO), which has secured special benefits in the deal. ...

Checkpoint Therapeutics (NASDAQ:CKPT) shares added more than 60% after it was revealed the immunology and targeted oncology firm will be acquired by Sun Pharmaceutical Industries. Under the agreement, Sun Pharma will acquire Checkpoint for $4.10 per share in cash, representing up to $355 million in upfront payments.

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Checkpoint (Nasdaq: CKPT) for possible breaches of fiduciary duty and other violations of law in its transaction with Sun Pharma. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction,...